Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19.

ABSTRACT:

Background and aims

Currently, there are no definitive therapies for coronavirus disease 2019 (COVID-19). Gut microbial dysbiosis has been proved to be associated with COVID-19 severity and probiotics is an adjunctive therapy for COIVD-19. However, the potential benefit of probiotics in COVID-19 has not been studied. We aimed to assess the relationship of probiotics use with clinical outcomes in patients with COVID-19.

Methods

We conducted a propensity-score matched retrospective cohort study of adult patients with COVID-19. Eligible patients received either probiotics plus standard care (probiotics group) or standard care alone (non-probiotics group). The primary outcome was the clinical improvement rate, which was compared among propensity-score matched groups and in the u

SUBMITTER: Zhang L 

PROVIDER: S-EPMC8351028 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature